Background-Experience of liver transplantation in haemophiliacs with end stage hepatitis C liver disease is limited and particularly difficult questions are raised when there is also HIV infection. Aims-This is the first report in Great Britain to describe the operative replacement therapy and initial outcome in four haemophiliacs with end stage HCV cirrhosis. Patients-Two patients had factor VIII, one had factor IX, and one had factor X deficiency. One patient had also contracted HIV infection from factor replacement but had no AIDS defining illnesses. Methods-Intraoperatively patients were given either factor VIII infusions, factor IX bolus, or fresh frozen plasma, according to formulae devised to calculate exact clotting factor requirements. Baseline preoperative coagulation studies included prothrombin time, activated partial thromboplastin time, fibrinogen concentrations, and factor VIII, IX, and X concentrations. Factor concentrations were then assayed at 12, 24, 48, and 72 hours postoperatively. Results-Postoperatively all patients had coagulation factor concentrations sustained within the normal ranges by 72 hours unsupported (137, 125, 95, 104 IU/di), representing de novo synthesis by the graft. Transfusion requirements during the operative and immediate posttransplant period were no greater than those of patients without clotting disorders. Two patients had episodes of bleeding postoperatively, one ofwhich was fatal, occurring at the site of a previous untreated subdural bleed. In both instances the bleeding occurred in the presence of normal concentrations of clotting factor. The remaining three patients are at 6, 6, and 12 months posttransplant and remarkably improved clinically with sustained factor concentrations. One patient has evidence of graft dysfunction from HCV recurrence and all have evidence of recurrent viraemia with HCV on polymerase chain reaction studies. Conclusions-Orthotopic liver transplantation should be considered in haemophiliac patients with end stage liver disease from hepatitis C infection with or without concomitant HIV infection. Their clinical condition is likely to be greatly improved by orthotopic liver transplantation and the haemophilia cured with only a small risk of severe graft dysfunction from recurrent HCV infection.
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Infection with hepatitis C virus (HCV) was virtually universal in haemophiliacs who received repeated pooled clotting factor concentrates until the introduction of more effective methods of viral inactivation (heat treatment in 1985, solvent detergent method in 1987) primarily designed to reduce the risk of HIV infection. Of the estimated 3200 haemophiliacs in the United Kingdom infected with HCV,' many are also coinfected with HIV.
Two recent reports suggest that HIV seropositivity in this group may be as high as 40-60%.3 3The estimated cumulative risk of developing hepatic decompensation in haemophiliacs with HCV infection is 1 7% at 10 years and 19.8% at 20 years after first exposure to the virus.3 However, data from Eysher et a12 showed that HCV infection can have a more aggressive course in those coinfected with HIV, with the incidence of liver failure increasing to 17% at 10 years. Risks of hepatic decompensation were greater with a more rapid decline in the CD4 count and the development of p24 antigenaemia, correlating with higher levels of viraemia. At the present time, only a minority of haemophiliacs in the United Kingdom have developed cirrhosis; however, it is likely that, over the next 5-10 years, even with the use of interferon, a sizeable number of these patients will progress to end stage liver disease and meet the requirements for orthotopic liver transplantation. After early animal studies in 1974 by Webster and colleagues, dogs with haemophilia B (factor IX deficiency) were transplanted, and these experiments showed that normal clotting function could be achieved post-transplantation. 4 To date, there have been seven reports of haemophiliacs being transplanted for end stage liver disease. Starzl's group reported the first two successful cases of transplantation in two patients with haemophilia and chronic liver disease between 1982 and 1985. This was followed by several reports of patients with both factor VIII and IX deficiency being given transplants.5-9 These earlier cases of transplantation for chronic liver disease were secondary to chronic hepatitis B infection as well as a non-A non-B hepatitis although not isolated as hepatitis C antibody positive at the time. Causes of death in these earlier cases included intraoperative bleeding and systemic sepsis. Despite the obvious benefits of correction of clotting disorder after liver transplantation, significant concerns have been expressed, including the risks of bleeding during transplantation, the frequent concomitant HIV infection, and the likely probability of recurrent HCV infection within the graft. We report here the clinical course and outcome of orthotopic liver transplantation in four haemophiliacs with end stage HCV cirrhosis, one of whom was HIV antibody positive, together with the unique factor replacement schedules used during and after surgery.
Methods
Between June 1994 and April 1995, four men, aged between 27 and 54 years and with haemophilia, underwent orthotopic liver transplantation. Of these, two had factor VIIIC deficiency (haemophilia A), one had factor IX deficiency (haemophilia B or Christmas disease), and one had mild factor X deficiency. No patient had a plasma inhibitor detected on routine coagulation studies. All four patients had decompensated end stage liver disease secondary to HCV infection, with positive HCV antibody and HCV RNA, the infection having been acquired through contaminated clotting factor infusions given before 1985. Patient 3 was known to be HIV antibody positive at the time of his transplantation, but had remained asymptomatic from his HIV disease and in particular, had had no AIDS defining illnesses since his diagnosis. CLOTTING (1 00-baseline value) Xbody weight (kg) This was supplemented by intermittent intravenous boluses intraoperatively as required. At 12 hours, if factor IX concentration was less than 30 IU then a 50 lU/kg bolus was given, if the concentration was greater than 30 IU but less than 50 IU then 25 lU/kg was given; once the concentration was greater than 50 IU no further supplement was required.
For patient 2, with mild factor X deficiency, the standard intraoperative transfusion regime for orthotopic liver transplantation was used, with fresh frozen plasma and platelets given as required. Four further units of fresh frozen plasma were given postoperatively to supplement factor X concentration and to keep the INR less than 1. 5.
SURGICAL TECHNIQUE
With the exception of patient 3, the standard orthotopic liver transplantation procedure with the use of venovenous bypass was performed. Patient 3 was younger and had normal renal function, allowing him to tolerate caval clamping more easily than the other patients. A further reason to avoid the use of bypass in this case was to limit the potential exposure of infective HIV blood products to the theatre staff. Techniques employed to minimise blood loss included the use of the cell saver to return washed red cells to the patients. Routine infective precautions were adhered to including the use of blunt needles in closure of the abdominal wound.
Case histories CASE 1 A 47 year old man with mild haemophilia A (factor VIIIC concentration of 23 IU/dl, NR 50-150) first became jaundiced in 1982 and was referred to King's College Hospital in 1991. At that time, his serum aspartate transaminase (AST) was raised to 500-600 IUAl and a liver biopsy showed features of an active cirrhosis. He was seropositive for both anti-HCV antibody (second generation immunosorbent assay (ELISA 2)) and HCV RNA (reverse transcriptase-polymerase chain reaction (RT-PCR)). He was treated with a-interferon for nine months, but had biochemical and virological relapse towards the end of that period. Over Figure) .
The preoperative concentration of factor X in patient 2 rose from 31 IU/dl and reached 54 IU/dl by 12 hours (NR 50-150 IU/dl). The patient received 16 units of fresh frozen plasma intraoperatively to supplement his factor X concentration but did not require any additional fresh frozen plasma post-transplantation. Concentrations were sustained at 24 hours at 72 IU/dl, representing graft synthesis of factor X. The patient's own production of factor X by his graft has maintained his concentrations within the normal range at up to six months without any intervening graft dysfunction.
Baseline factor IX concentration in patient 4 rose from 3 IU/dl to 68 IU/dl at 12 hours (normal range 50-150 IU/dl). He required one intraoperative bolus of factor IX concentrate but by 12 hours he was synthesising adequate concentrations by his own graft. At 24 and 48 hours, concentrations were similarly maintained within the normal range at 81 and 113 IU/dl. Measurements on samples taken within two hours of his intracerebral bleed confirmed that factor IX concentration had still been maintained within an accepted normal range at 104 IU/dl, suggesting that, despite a recent episode of graft dysfunction from acute rejection, his concentration had not fallen and contributed to the bleed. Concentrations had therefore been maintained up to 18 days in this patient.
INTRAOPERATIVE LOSSES AND SUPPLEMENTS
Intraoperative blood losses for the four patients during transplantation were similar to other patients without clotting disorders (Table II) . Similarly, this group of patients did not require any additional supplementation with blood 1  7h35min  4620  6  0  10  0  2   6h28min  5940  8  0  16  0  3  5h30min  5090  3  3  4  0   4  6 h 30 min  4028  6  2  16  12 products (apart from fresh frozen plasma for patient 2) than those without clotting disorders, confirming that from a haemostatic point of view they were at no greater risk of bleeding during the procedure itself. early as 12 hours and in all cases had been sustained within a normal therapeutic range by 72 hours. As the half life of factors VIII, IX, and X are all less than 72 hours, this must represent de novo synthesis of factor by the new graft. Although graft dysfunction will result in impairment of clotting factor production leading to decreased plasma concentration, this does not apply to factor VIII in these situations as it often acts as an acute phase reactant, resulting in an initial rise in serum concentration. Similarly, in patients with fulminant hepatic failure due to a viral hepatitis, increases in factor VIII concentration are seen compared with the other factors, which are reduced. Likely mechanisms for this effect are an increased synthesis secondary to cytokine release.
Given current statistics and treatment an increasing proportion of patients with HIV infection will survive up to 10 years after seroconversion without developing AIDS'l and the proportion coinfected with HCV are more likely to die as a result of end stage liver disease than HIV complications. HIV used to be regarded as an absolute contraindication to transplantation, as patients were thought to be at an increased risk of opportunistic infections. However, patients have now been successfully transplanted who were knowingly or unknowingly HIV antibody positive at the time of transplantation."`12 In a recent review by Schwartz and colleagues, of 53 transplanted patients with HIV infection caused by either a blood transfusion or an infected transplant, the cumulative incidence of developing the AIDS syndrome was significantly lower in the 40 who received cyclosporin A as part of the immunosuppression regimen (31 %) than in 13 patients not given cyclosporin (90%).12 The best long term data currently on survival of HIV positive transplanted patients is from Starzl and colleagues" who reviewed 25 transplanted patients who were either HIV positive before transplantation or who seroconverted postoperatively. Of the 15 who had had liver transplants, seven were known to be HIV positive at the time of transplant and eight later seroconverted after their transplant. When this group was compared with liver transplants overall, there was no difference in survival at one year but by five years survival was 53% in the HIV positive group compared with 63% overall. In vitro studies have shown that both cyclosporin and tacrolimus (FK506) reduce cell to cell transmission of HIV-1 virus and can also significantly reduce the yield of infectious HIV by 100-fold. ' 
